Survival of thalassemic patients referred to the Boo Ali Sina Teaching Hospital, Sari, Iran.
Beta-thalassemia major (TM) is the most prevalent genetic disease in Mazandaran Province. Currently, about 2,700 TM patients have been registered and are under treatment in the province. This study was undertaken to evaluate the survival of patients attending a dedicated clinic at the Boo Ali Sina Teaching Hospital, Sari, Iran, which was established in 1986. This survival analysis was conducted from July 2004 to September 2006. New deaths were updated in September 2006. A total of 1,010 medical records were reviewed. Place of residence, date of birth, first transfusion, initiation date of chelation, diagnosis of cardiac complications, diabetes and death were recorded. Compliance to treatment assessed by calculating the percentage of actual usage to prescribed iron chelator medicine and also by asking the attending nurse who was constantly present throughout the last 15 years. Validity of the opinion of the nurse was ascertained in a previous study. Kaplan-Meier statistics were used for analysis. The odds ratio (OR) and its 95% confidence interval (CI) for some risk factors of death were calculated. The survival rate of patients born before and after 1986 was also compared. Survival of both genders for birth cohort before and after 1986 was not statistically significant although the cohort of patients born after 1986 was better at 30 years old (68 vs. 80%). The survival of TM patients is improving but the prevalence of complications is high.
Kosaryan
Mehrnoosh
M
Thalassemia Research Center, Mazandaran University of Medicine, Sari, Mazandaran, Iran. kvahidshahi@yahoo.com
Vahidshahi
Koorosh
K
Karami
Hosein
H
Forootan
Morteza Alizadeh
MA
Ahangari
Mehdi
M
D000293:Adolescent; D000328:Adult; D001803:Blood Transfusion; D016026:Bone Marrow Transplantation; D009202:Cardiomyopathies / Q000150:complications; D015913:Chelation Therapy; D002648:Child; D002675:Child, Preschool; D048909:Diabetes Complications; D006784:Hospitals, Teaching; D006801:Humans; D007492:Iran; D007502:Iron Chelating Agents / Q000627:therapeutic use; D008875:Middle Aged; D012307:Risk Factors; D013156:Splenectomy; D016019:Survival Analysis; D017086:beta-Thalassemia / Q000150:complications / Q000188:drug therapy / Q000401:mortality* / Q000601:surgery
D007502:Iron Chelating Agents